GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports

The Firm is investigating Fresenius GranuFlo lawsuits on behalf of dialysis patients who allegedly experienced cardiac arrest, heart attacks, stroke, sudden cardiac death, or other side effects related to last year’s GranuFlo and NaturaLyte recall.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
We are not surprised that the number of GranuFlo lawsuits filed in this litigation have surpassed 300.

New York, New York (PRWEB) July 10, 2013

GranuFlo lawsuit claims filed in the wake of Fresenius Medical Care’s GranuFlo and NaturaLyte dialysis drug recall have begun to move forward in a federal multidistrict litigation underway in the U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. Court records indicate that more than 300 Fresenius Granuflo lawsuits are now pending in the multidistrict litigation. On June 21st, a motion was filed with the Court asking U.S. District Judge Douglas P. Woodlock to schedule the proceeding’s Initial Case Management Conference, and to name plaintiffs’ attorneys to leadership positions in the litigation. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“We are not surprised that the number of GranuFlo lawsuits filed in this litigation have surpassed 300. Our Firm continues to hear from patients affected by the GranuFlo and NaturaLyte recall who have experienced catastrophic heart problems, allegedly due to the administration of these drugs,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the GranuFlo and NaturaLyte recall.

GranuFlo and NaturaLyte Recall
All of the Fresenius GranuFlo lawsuits pending in the District of Massachusetts allege Fresenius Medical Care was aware of the heart risks associated with GranuFlo and NaturaLyte, but failed to provide adequate warnings regarding those risks. Both GranuFlo and Naturalyte were the subject of an “Urgent Product Notification” Fresenius issued to its customer clinics in March of 2012 that warned of possible heart risks associated with the products. The U.S. Food & Drug Administration (FDA) later deemed the notification a Class I recall, its most serious class of safety alert. According to the FDA, dialysis patients treated with GranuFlo and NaturaLyte may experience elevated levels of bicarbonate in the blood, which can lead to catastrophic heart side effects, including cardiopulmonary arrest and sudden cardiac death.*

According to a New York Times report published in June 2012, Fresenius Medical Care treats more than a third of the estimated 400,000 Americans receiving dialysis and is the leading supplier of dialysis machines and disposable products. The FDA launched an investigation into the timing of the GranuFlo and NaturaLyte recall, after learning that Fresenius had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with the drugs, and advised doctors to adjust their dosage to avoid these dangers. A similar warning was not issued by the company to its customer clinics at that time, the Times reported.**

Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to compensation for their injuries. To learn more about filing a Fresenius GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website. For additional information, and to arrange for a free legal consultation, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

*fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm; FDA, March 29, 2013
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html;

New York Times, June 14, 2012
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflodialysislawsuits.com/